[Lead poisoning in adults. Experience of the Poison Control Center of Marseille from 1993 to 2000]. 2001

L de Haro, and N Prost, and D Gambini, and J H Bourdon, and M Hayek-Lanthois, and M Valli, and J Jouglard, and J Arditti
Centre antipoison, Hôpital Salvator, 249 Bd Sainte Marguerite, F13274 Marseille.

OBJECTIVE Report the experience of the Marseille's anti-poison center with lead poisoning adults. METHODS Between 1993 and 2000, 45 adults patients consulted the poison Centre of Marseille for a history of lead exposure (9 women, 36 men, average age 44 YO, between 22 an 76 YO). The lead sources were mostly occupational (welding, heavy metal industries...), but some were environmental (shooting as a hobby, hunting,...). RESULTS Ninety-one percent of the patients presented with a clinical feature of possible lead intoxication (asthenia, abdominal pain, anaemia, seizures,...). For 22 patients, calcitetracemate provocation test was negative. 6 patients with a positive test refused to be treated. 16 patients with a positive test were treated with chelation therapy (average lead blood level 566 micrograms/l--mini 320 micrograms/l, maxi 943 micrograms/l--and average lead urine elimination 3,011 micrograms/24 H--mini 789 micrograms/24 H, maxi 7,229 micrograms/24 H. 58 cures were done (1 to 12 cures for each patient). The average quantities of lead eliminated in the urine during the chelation therapy was 30,912 micrograms +/- 29,059 micrograms by case. For 12 patients who stopped the lead exposure after the diagnosis of lead poisoning, the chelaion therapy permitted to decrease the lead blood level of 69%. For 4 patients still exposed during the treatment, the lead blood level decrease of 7% only. For the 16 treated patiEnts, a clinical improvement was noted, and no adverse effects of chelation therapy was observed during the 58 cures.

UI MeSH Term Description Entries
D007855 Lead Poisoning Poisoning that results from chronic or acute ingestion, injection, inhalation, or skin absorption of LEAD or lead compounds. Poisoning, Lead,Lead Poisonings,Poisonings, Lead
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011039 Poison Control Centers Facilities which provide information concerning poisons and treatment of poisoning in emergencies. Centers, Poison Control,Center, Poison Control,Control Centers, Poison,Poison Control Center
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002614 Chelating Agents Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. Chelating Agent,Chelator,Complexons,Metal Antagonists,Chelators,Metal Chelating Agents,Agent, Chelating,Agents, Chelating,Agents, Metal Chelating,Antagonists, Metal,Chelating Agents, Metal
D005260 Female Females
D005602 France A country in western Europe bordered by the Atlantic Ocean, the English Channel, the Mediterranean Sea, and the countries of Belgium, Germany, Italy, Spain, Switzerland, the principalities of Andorra and Monaco, and by the duchy of Luxembourg. Its capital is Paris. Corsica,Saint Pierre and Miquelon,Miquelon and Saint Pierre,Miquelon and St. Pierre,St. Pierre and Miquelon
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

L de Haro, and N Prost, and D Gambini, and J H Bourdon, and M Hayek-Lanthois, and M Valli, and J Jouglard, and J Arditti
January 1989, Journal de toxicologie clinique et experimentale,
L de Haro, and N Prost, and D Gambini, and J H Bourdon, and M Hayek-Lanthois, and M Valli, and J Jouglard, and J Arditti
September 2019, Presse medicale (Paris, France : 1983),
L de Haro, and N Prost, and D Gambini, and J H Bourdon, and M Hayek-Lanthois, and M Valli, and J Jouglard, and J Arditti
January 1979, Therapie,
L de Haro, and N Prost, and D Gambini, and J H Bourdon, and M Hayek-Lanthois, and M Valli, and J Jouglard, and J Arditti
November 2009, Presse medicale (Paris, France : 1983),
L de Haro, and N Prost, and D Gambini, and J H Bourdon, and M Hayek-Lanthois, and M Valli, and J Jouglard, and J Arditti
November 2001, Presse medicale (Paris, France : 1983),
L de Haro, and N Prost, and D Gambini, and J H Bourdon, and M Hayek-Lanthois, and M Valli, and J Jouglard, and J Arditti
April 2020, Fundamental & clinical pharmacology,
L de Haro, and N Prost, and D Gambini, and J H Bourdon, and M Hayek-Lanthois, and M Valli, and J Jouglard, and J Arditti
April 2020, Fundamental & clinical pharmacology,
L de Haro, and N Prost, and D Gambini, and J H Bourdon, and M Hayek-Lanthois, and M Valli, and J Jouglard, and J Arditti
January 1989, Journal de toxicologie clinique et experimentale,
L de Haro, and N Prost, and D Gambini, and J H Bourdon, and M Hayek-Lanthois, and M Valli, and J Jouglard, and J Arditti
January 2013, Journal of agromedicine,
L de Haro, and N Prost, and D Gambini, and J H Bourdon, and M Hayek-Lanthois, and M Valli, and J Jouglard, and J Arditti
January 2000, Therapie,
Copied contents to your clipboard!